- Home
- IDA vs CDTX Comparison
IDA vs CDTX Comparison
Compare IDA & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDA | CDTX |
|---|---|---|
| Founded | 1915 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.9B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | IDA | CDTX |
|---|---|---|
| Price | $126.33 | $220.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $135.43 | $128.75 |
| AVG Volume (30 Days) | 439.8K | ★ 1.1M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 7.17 | N/A |
| EPS | ★ 5.84 | N/A |
| Revenue | ★ $1,805,885,000.00 | N/A |
| Revenue This Year | $6.64 | N/A |
| Revenue Next Year | $7.70 | N/A |
| P/E Ratio | $21.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $104.74 | $15.22 |
| 52 Week High | $138.03 | $221.20 |
Technical Indicators
Market Signals| Indicator | IDA | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 85.84 |
| Support Level | $124.84 | $219.91 |
| Resistance Level | $128.50 | $220.78 |
| Average True Range (ATR) | 2.19 | 0.71 |
| MACD | 0.10 | -4.33 |
| Stochastic Oscillator | 25.80 | 70.62 |
Price Performance
Historical ComparisonAbout IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.